Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

1. Clozapine versus risperidone for people with schizophrenia [Cochrane protocol]

Clozapine versus risperidone for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

2. Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis

Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

3. Efficacy and side effects of risperidone use in autism spectrum disorder: a systematic review and meta-analysis

Efficacy and side effects of risperidone use in autism spectrum disorder: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

4. Risperidone

Risperidone Top results for risperidone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for risperidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). (PubMed)

Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation.To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation.We searched the Cochrane (...) of risperidone and other drugs, combinations of drugs or placebo for people exhibiting aggression or agitation (or both) thought to be due to psychosis.We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all with 95% confidence intervals (CI) and used a fixed-effect model. We assessed risk of bias

2018 Cochrane

6. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. (PubMed)

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used (...) in people with serious mental illness and co-occurring substance misuse.On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers).We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our

2018 Cochrane

7. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. (PubMed)

In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. 28320006 2017 12 08 2018 12 02 1539-3704 166 6 2017 03 21 Annals of internal medicine Ann. Intern. Med. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. JC32 10.7326/ACPJC-2017-166-6-032 Lee Justin J Holbrook Anne A McMaster UniversityHamilton, Ontario, Canada. eng Journal Article Comment United States Ann Intern Med 0372351 0003-4819 (...) 0 Antipsychotic Agents J6292F8L3D Haloperidol L6UH7ZF8HC Risperidone AIM IM JAMA Intern Med. 2017 Jan 1;177(1):34-42 27918778 Antipsychotic Agents Delirium Double-Blind Method Haloperidol Humans Palliative Care Risperidone 2017 3 21 6 0 2017 3 21 6 0 2017 12 9 6 0 ppublish 28320006 2612421 10.7326/ACPJC-2017-166-6-032

2017 Annals of Internal Medicine Controlled trial quality: uncertain

8. Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations (PubMed)

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations Case 1: A 20-year-old woman suffering a suspected overdose was transported to the hospital. She presented bradycardia with wide QRS waves and QT prolongation, followed by cardiac arrest. Extracorporeal cardiopulmonary resuscitation was implemented, improving circulation. Risperidone and 9OH-RIS levels were 9.6 ng/mL and 127.6 ng/mL, respectively. Case 2: A 54 (...) -year-old woman was hospitalized for femoral fracture and underwent surgery. Her electrocardiogram showed bradycardia and complete AV block. Risperidone and 9OH-RIS levels were 3.2 ng/mL and 61.4 ng/mL, respectively.In both cases, only serum concentration of 90H-RIS were elevated.Arrhythmia related to risperidone has proven rare but sometimes fatal. Serum concentrations of risperidone and the metabolite 9-hydroxy-risperidone (9OH-RIS) during these events are seldom documented. As 9OH-RIS shows

Full Text available with Trip Pro

2017 Acute medicine & surgery

9. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. (PubMed)

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms.In this randomised, double-blind, phase 3b trial, we enrolled (...) adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous

2017 Lancet Controlled trial quality: predicted high

10. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. (PubMed)

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%.To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children.In a 6-week double (...) -blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners' Parent Rating Scale (CPRS-48), Children's Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher's exact tests in the SPSS 19

Full Text available with Trip Pro

2016 Electronic physician Controlled trial quality: uncertain

11. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. (PubMed)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.Thirty patients taking risperidone were enrolled (...) improved erectile dysfunction in five out of six patients. There were no significant differences in change in psychopathology or side-effects between groups.Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. This is a potential treatment for hyperprolactinaemia observed during treatment with second-generation antipsychotics.None.© The Royal College of Psychiatrists 2015. This is an open access article

Full Text available with Trip Pro

2016 BJPsych open Controlled trial quality: uncertain

12. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. (PubMed)

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

Full Text available with Trip Pro

2016 Cochrane

13. Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis. (PubMed)

Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis. 27409138 2017 03 13 2018 12 02 2238-0019 38 2 2016 Apr-Jun Trends in psychiatry and psychotherapy Trends Psychiatry Psychother Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis. 114-6 10.1590/2237-6089-2015-0068 S2237-60892016000200114 Soares Amanda A Laboratório de Neuromodulação Clínica (...) , Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil. Cordeiro Quirino Q Laboratório de Neuromodulação Clínica, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil. eng Letter Meta-Analysis Review Systematic Review Brazil Trends Psychiatry Psychother 101610695 2237-6089 0 Psychotropic Drugs L6UH7ZF8HC Risperidone IM Autistic Disorder drug therapy Drug Therapy, Combination Humans Psychotropic Drugs therapeutic use Risperidone therapeutic use 2015 10

Full Text available with Trip Pro

2016 Trends in psychiatry and psychotherapy

14. Risperidone (depot) for schizophrenia. (PubMed)

Risperidone (depot) for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for schizophrenia.We searched the Cochrane (...) Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015). We also checked the references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like psychoses.Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk ratio (RR), with 95% confidence interval (CI

Full Text available with Trip Pro

2016 Cochrane

15. Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis

Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis Long-acting injectable risperidone as an option in first-episode psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting injectable risperidone as an option in first-episode psychosis Article Text Electronic pages Pharmacological interventions Long-acting injectable risperidone as an option in first-episode psychosis Nancy H

2016 Evidence-Based Mental Health

16. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Article Text Causes and risk factors Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D 2/3 receptor occupancy following risperidone and olanzapine dose reduction Hiroyoshi Takeuchi , Gary Remington Statistics from Altmetric.com ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al . Evaluation of antipsychotic

2015 Evidence-Based Mental Health

17. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia HAS - Medical, Economic and Public Health Assessment Division 1/16 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated tablet B/60 (CIP (...) for injection in prefilled syringe B/1 (CIP: 34009 362 494 2 4) HAS - Medical, Economic and Public Health Assessment Division 2/16 Applicant: JANSSEN-CILAG INN Risperidone ATC code N05AX08 (Antipsychotics) Reason for the review Renewal of inclusion Extension of indication in the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer's dementia unresponsive to non pharmacological approaches and when there is a risk of harm to self or others. Lists

2014 Haute Autorite de sante

18. Risperidone

Risperidone USE OF RISPERIDONE IN PREGNANCY 0344 892 0909 USE OF RISPERIDONE IN PREGNANCY (Date of issue: January 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Risperidone is an atypical antipsychotic used in the treatment (...) of schizophrenia, mania, and for the short term management of persistent aggression. Although risperidone exposures are included in a number of studies which report on fetal outcome for cohorts of women exposed to various antipsychotics, the percentage and absolute number of risperidone exposures in each of these cohorts is generally very small and no separate analysis for risperidone was undertaken. The very limited data that are available for risperidone specifically do not provide evidence of an increased

2014 UK Teratology Information Service

19. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD

Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) to augmentation with risperidone for treating adults with treatment-resistant OCD Article Text Psychological interventions Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Joseph O'Neill Statistics from Altmetric.com What is already known on this topic? For adult patients with obsessive-compulsive disorder (OCD) resistant to serotonin reuptake inhibitors (SRIs), American Psychological Association practice

2014 Evidence-Based Mental Health

20. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.